References:
1. Stieglitz E, Taylor-Weiner AN, Chang TY, et al. The genomic landscape
of juvenile myelomonocytic leukemia. Nat Genet. 2015;47(11):1326-1333.2. Chan RJ, Cooper T, Kratz CP, Weiss B, Loh ML.
Juvenile myelomonocytic leukemia: a report from the 2nd International
JMML Symposium. Leuk Res. 2009;33(3):355-362.3. Swerdlow SH CE,
Harris NL, Jaffe ES, Pileri SA, Stein H, et al. . WHO
Classification of Tumours of Haematopoietic and Lymphoid Tissues,
Revised Fourth Edition. Vol 2. Lyon, France: IARC/WHO Press; 2017.4.
Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health
Organization Classification of Haematolymphoid Tumours: Myeloid and
Histiocytic/Dendritic Neoplasms. Leukemia. 2022;36(7):1703-1719.5. Locatelli F, Niemeyer CM. How I treat juvenile
myelomonocytic leukemia. Blood. 2015;125(7):1083-1090.6.
Wintering A, Dvorak CC, Stieglitz E, Loh ML. Juvenile myelomonocytic
leukemia in the molecular era: a clinician’s guide to diagnosis, risk
stratification, and treatment. Blood Adv. 2021;5(22):4783-4793.7.
Rudelius M, Weinberg OK, Niemeyer CM, Shimamura A, Calvo KR. The
International Consensus Classification (ICC) of hematologic neoplasms
with germline predisposition, pediatric myelodysplastic syndrome, and
juvenile myelomonocytic leukemia. Virchows Arch. 2023;482(1):113-130.8. Leguit RJ, Orazi A, Kucine N, et al. EAHP 2020
workshop proceedings, pediatric myeloid neoplasms. Virchows Arch. 2022;481(4):621-646.9. Chao AK, Meyer JA, Lee AG, et al. Fusion driven
JMML: a novel CCDC88C-FLT3 fusion responsive to sorafenib identified by
RNA sequencing. Leukemia. 2020;34(2):662-666.10. Arber DA, Orazi
A, Hasserjian RP, et al. International Consensus Classification of
Myeloid Neoplasms and Acute Leukemias: integrating morphologic,
clinical, and genomic data. Blood. 2022;140(11):1200-1228.11.
Hollink IH, van den Heuvel-Eibrink MM, Arentsen-Peters ST, et al.
NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid
leukemia with a distinct HOX gene expression pattern. Blood. 2011;118(13):3645-3656.12. Arber DA, Hasserjian RP, Orazi A, et al.
Classification of myeloid neoplasms/acute leukemia: Global perspectives
and the international consensus classification approach. Am J
Hematol. 2022;97(5):514-518.13. Hoshino Y, Moriya K, Mitsui-Sekinaka K,
et al. Noonan Syndrome-related Myeloproliferative Disorder Occurring in
the Neonatal Period: Case Report and Literature Review. J Pediatr
Hematol Oncol. 2024;46(2):e176-e179.14. Lucas BJ, Connors JS, Wang H,
et al. Observation and Management of Juvenile Myelomonocytic Leukemia
and Noonan Syndrome-Associated Myeloproliferative Disorder: A Real-World
Experience. Cancers (Basel). 2024;16(15).15. Bugarin C, Antolini
L, Buracchi C, et al. Phenotypic profiling of CD34(+) cells by advanced
flow cytometry improves diagnosis of juvenile myelomonocytic leukemia.Haematologica. 2024;109(2):521-532.16. Kratz CP, Niemeyer CM,
Castleberry RP, et al. The mutational spectrum of PTPN11 in juvenile
myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease.Blood. 2005;106(6):2183-2185.17. Stieglitz E, Lee AG, Angus SP,
et al. Efficacy of the Allosteric MEK Inhibitor Trametinib in Relapsed
and Refractory Juvenile Myelomonocytic Leukemia: a Report from the
Children’s Oncology Group. Cancer Discov. 2024:OF1-OF9.18.
Stieglitz E, Ward AF, Gerbing RB, et al. Phase II/III trial of a
pre-transplant farnesyl transferase inhibitor in juvenile myelomonocytic
leukemia: a report from the Children’s Oncology Group. Pediatr
Blood Cancer. 2015;62(4):629-636.